French Validation of the AdT-Physio Scale (Trans-AdT)

March 17, 2024 updated by: Pole Sante Grace de Dieu

French Validation of the AdT-Physio Scale for Assessing Adherence and Perception of the Intervention of a Physiotherapist in Patients With Cystic Fibrosis

The goal of this observational study is to translate and validate the Adt-Physio scale in French, and to validate on a large number of patients the French translation of the Adt-Physio scale as a tool for evaluating adherence and perception of the intervention of a physiotherapist in patients with cystic fibrosis.

participants will have to answer the French trans-AdT scale, the Brief Cope and GSES questionnaire.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Cystic fibrosis is one of the most frequently encountered rare genetic diseases. In 2022, this pathology affected 7,743 people in the French population, i.e. 3% more than in 2021. Previously, this fatal disease only granted a few months of life to child carriers. Today, the median age at death is over 40 years old. The adult population suffering from cystic fibrosis has thus become more numerous than the pediatric population. Among existing treatments, respiratory and musculoskeletal massage physiotherapy occupies a central place in patients' lives. However, the level of adherence to massage physiotherapy is low among young adults (16 to 21 years old) compared to other types of treatments. Faced with epidemiological changes and the daily burden that this chronic pathology represents for those affected, therapeutic adherence should be a major concern for physiotherapists. Indeed, a low level of adherence would increase treatment failures, the risk of premature death, episodes of exacerbations and hospitalizations and would thus reduce quality of life. It is therefore crucial to have means of assessing this parameter in patients with cystic fibrosis. The AdT physio self-assessment questionnaire, validated in Spanish since 2020, has shown clinical validity and reliability for Spanish-speaking patients. Thus, a version of this scale translated and validated in French would offer physiotherapists a relevant tool allowing them to evaluate therapeutic adherence and the perception of their interventions with French-speaking patients suffering from cystic fibrosis.

Study Type

Observational

Enrollment (Estimated)

121

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Caen, France, 14000
        • PSLA GDD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The subjects recruited are patients with cystic fibrosis, over 18 years old, without a lung transplant and able to answer the questionnaires.

Description

Inclusion Criteria:

The subjects recruited are patients with cystic fibrosis, over 18 years old, without a lung transplant and able to answer the questionnaires.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
AdT-Physio scale (Adherence to Treatment of Physiotherapy scale)
Time Frame: 1 year
set of 15 questions divided into two sets, one focusing on patient adherence and the other on beliefs about the treatment and therapist (The total score on the final version of the AdT-Physio scale can range from 14 to 56, in which a high score is indicative of better adherence to physical therapy.)
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pole Sante Grace de Dieu

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2024

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

July 31, 2025

Study Registration Dates

First Submitted

February 8, 2024

First Submitted That Met QC Criteria

February 15, 2024

First Posted (Actual)

February 22, 2024

Study Record Updates

Last Update Posted (Actual)

March 19, 2024

Last Update Submitted That Met QC Criteria

March 17, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20230202

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cystic Fibrosis

Clinical Trials on Questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe